GHRH Peptide Antagonists Make Chemotherapy More Effective Against Multiple Cancers | Research

The takeaway

Synthetic GHRH receptor antagonists enhanced the effectiveness of multiple chemotherapy drugs across breast, lung, and colorectal cancer models by reducing drug resistance and inflammatory signaling.

Enhanced 5 different chemotherapy drugs
GHRH antagonists potentiated doxorubicin, docetaxel, 5-FU, irinotecan, and cisplatin across breast, lung, and colorectal cancer models by reducing drug resistance and survival signaling.

What the researchers found

GHRH antagonists potentiate the efficacy of chemotherapy agents such as doxorubicin, docetaxel, 5-FU, irinotecan, and cisplatin by reducing tumor growth, inflammatory signaling, drug resistance gene expression, cancer stem-cell markers, and efflux pump function in various cancer models including triple negative breast cancer, non-small cell lung cancer, and colorectal cancer.

Why it matters

This research suggests that targeting GHRH receptors could improve chemotherapy effectiveness, potentially leading to better cancer treatment outcomes and overcoming drug resistance.

How the study worked

The study used in vitro cancer cell lines and in vivo mouse xenograft models treated with GHRH antagonists alone or combined with chemotherapy drugs to assess tumor growth, gene expression, cell cycle arrest, and drug resistance mechanisms.

What this study cannot tell us

The study was conducted primarily in cell lines and mouse models, so clinical efficacy and safety in humans remain to be established.

How to read the evidence

This is a preclinical study using cancer cell lines and mouse xenograft models. While the results are consistent across multiple cancer types and chemotherapy agents, human clinical validation is needed.

When this study was published

Published in 2015 by Andrew Schally (Nobel laureate in peptide hormone research), this work established the concept of GHRH antagonists as chemotherapy sensitizers. Subsequent research may have advanced this toward clinical testing.

The bigger picture

GHRH antagonists represent a unique approach to cancer therapy — targeting a peptide hormone pathway that cancers hijack for growth. The finding that these antagonists also overcome chemotherapy resistance addresses one of the biggest challenges in oncology. If confirmed clinically, combining GHRH antagonists with standard chemotherapy could improve outcomes for patients with drug-resistant cancers, opening a new therapeutic niche for peptide-based oncology.

Questions still open

Are GHRH antagonists being tested in clinical trials as chemotherapy sensitizers?
Which specific cancer types would benefit most from GHRH antagonist combination therapy?
Could GHRH agonists like tesamorelin inadvertently promote cancer growth in patients with undiagnosed malignancies?

Common questions

How can blocking a growth hormone peptide help fight cancer?

Many cancers produce their own GHRH — a peptide normally made by the brain to stimulate growth hormone release. Cancers use GHRH as a local growth signal, acting through GHRH receptors on the tumor cells themselves. Blocking these receptors with synthetic antagonists removes this growth signal and, crucially, also makes cancer cells more vulnerable to chemotherapy by reducing their resistance mechanisms.

Could GHRH antagonists replace chemotherapy?

No — the antagonists work best in combination with chemotherapy, not as replacements. They enhance chemotherapy's effectiveness by making cancer cells more susceptible to the drugs. Think of them as removing the cancer's shield, allowing chemotherapy to hit harder. Used alone, they slow tumor growth but don't eliminate it as effectively as the combination.

Read the original research

Potentiating effects of GHRH analogs on the response to chemotherapy.

Cell cycle (Georgetown, Tex.), 14(5), 699-704

View on PubMed ↗Publisher’s paper ↗

Citation

Schally, Andrew V; Perez, Roberto; Block, Norman L; Rick, Ferenc G. (2015). Potentiating effects of GHRH analogs on the response to chemotherapy.. Cell cycle (Georgetown, Tex.), 14(5), 699-704. https://doi.org/10.1080/15384101.2015.1010893